J. P. Soulier and M. C. Boffa, Avortements à répétition, thrombose et anticoagulants circulants antithromboplastines, Nouv. Presse Mdd, vol.9, pp.859-864, 1980.

D. Alarcón-segovia, M. E. Pérez-vázquez, A. R. Villa, C. Drenkard, and J. Cabiedes, Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus, Semin Arthritis Rheum. avr, vol.21, issue.5, pp.275-86, 1992.

D. Alarcón-segovia, Clinical manifestations of the antiphospholipid syndrome, J Rheumatol. nov, vol.19, issue.11, pp.1778-81, 1992.

W. A. Wilson, A. E. Gharavi, T. Koike, M. D. Lockshin, D. W. Branch et al., International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop, Arthritis Rheum. juill, vol.42, issue.7, pp.1309-1320, 1999.

S. Miyakis, M. D. Lockshin, T. Atsumi, D. W. Branch, R. L. Brey et al., International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome

, J Thromb Haemost JTH. févr, vol.4, issue.2, pp.295-306, 2006.

V. Salle, Syndrome des antiphospholipides « séronégatif » : mythe ou réalité ?, Rev Médecine Interne. 1 avr, vol.41, issue.4, pp.265-74, 2020.

I. W. Uthman and A. E. Gharavi, Viral infections and antiphospholipid antibodies, Semin Arthritis Rheum. févr, vol.31, issue.4, pp.256-63, 2002.

D. Sène, J. Piette, and P. Cacoub, Antiphospholipid antibodies, antiphospholipid syndrome and infections, Autoimmun Rev. 1 févr, vol.7, issue.4, pp.272-279, 2008.

K. Tanizawa, D. Nakatsuka, E. Tanaka, T. Inoue, M. Sakuramoto et al., Pulmonary thrombosis with transient antiphospholipid syndrome after mononucleosis-like illness, Intern Med Tokyo Jpn, vol.48, issue.14, pp.1231-1235, 2009.

Y. Asano, M. Sarukawa, T. Idezuki, S. Harada, K. Kaji et al., Multiple small pulmonary emboli associated with transient antiphospholipid syndrome in human Parvovirus B19 infection, Clin Rheumatol. juill, vol.25, issue.4, pp.585-592, 2006.

J. A. Gómez-puerta, G. Espinosa, and R. Cervera, Antiphospholipid Antibodies: From General Concepts to Its Relation with Malignancies, Antibodies Basel Switz. 2 août, vol.5, issue.3, 2016.

M. M. Abreu, A. Danowski, D. G. Wahl, M. Amigo, M. Tektonidou et al., The relevance of « non-criteria » clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features, Autoimmun Rev. mai, vol.14, issue.5, pp.401-415, 2015.

M. Noureldine, W. Nour-eldine, M. A. Khamashta, and I. Uthman, Insights into the diagnosis and pathogenesis of the antiphospholipid syndrome, Semin Arthritis Rheum, vol.48, issue.5, pp.860-866, 2019.

G. N. Dalekos, K. Zachou, and C. Liaskos, The antiphospholipid syndrome and infection, Curr Rheumatol Rep. août, vol.3, issue.4, pp.277-85, 2001.

J. C. Piette, diagnostic and classification criteria for the antiphospholipid/cofactors syndrome: a "mission impossible'? Lupus, vol.5, pp.354-63, 1996.

A. Talathi, S. Lopez-olivo, M. A. Suarez-almazor, and M. E. , Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis, Lupus. avr, vol.27, issue.4, pp.572-83, 2018.

M. G. Tektonidou, L. Andreoli, M. Limper, Z. Amoura, R. Cervera et al., EULAR recommendations for the management of antiphospholipid syndrome in adults, Ann Rheum Dis, vol.78, issue.10, pp.1296-304, 2019.

R. Osteresch, A. Fach, R. Hambrecht, and H. Wienbergen,

, Herz. déc, vol.44, issue.8, pp.696-700, 2019.

V. Pengo, A. Banzato, E. Bison, G. Zoppellaro, P. Jose et al., Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial, Lupus. mars, vol.25, issue.3, pp.301-307, 2016.

L. Persijn, A. Decavele, S. Schouwers, and K. Devreese, Evaluation of a new set of automated chemiluminescense assays for anticardiolipin and anti-beta2-glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome, Thromb Res. déc, vol.128, issue.6, pp.565-574, 2011.

J. T. Brandt, L. K. Barna, and D. A. Triplett, Laboratory identification of lupus anticoagulants: results of the Second International Workshop for Identification of Lupus Anticoagulants, On behalf of the Subcommittee on Lupus Anticoagulants/Antiphospholipid Antibodies of the ISTH, vol.74, pp.1597-603, 1995.

V. Pengo, A. Tripodi, G. Reber, J. H. Rand, T. L. Ortel et al., Update of the guidelines for lupus anticoagulant detection, Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis, vol.7, pp.1737-1777, 2009.

L. Durcan and M. Petri, Epidemiology of the Antiphospholipid Syndrome, Antiphospholipid syndrome insystemic autoimmune diseases, pp.17-30, 2016.

R. Cervera, M. Boffa, M. A. Khamashta, and G. Hughes, The Euro-Phospholipid project: epidemiology of the antiphospholipid syndrome in Europe, Lupus. sept, vol.18, issue.10, pp.889-93, 2009.

A. Duarte-garcía, M. M. Pham, C. S. Crowson, S. Amin, K. G. Moder et al., The Epidemiology of Antiphospholipid Syndrome: A Population-Based Study, Arthritis Rheumatol Hoboken NJ, vol.71, issue.9, pp.1545-52, 2019.

K. Paramsothy and P. S. Wells, Prevalence of Antiphospholipid Anitbodies in Idiopathic Venous Thromboembolism, Blood, vol.104, issue.11, pp.529-529, 2004.

A. Danowski, T. S. Kickler, and M. Petri, Anti-beta2-glycoprotein I: prevalence, clinical correlations, and importance of persistent positivity in patients with antiphospholipid syndrome and systemic lupus erythematosus, J Rheumatol. sept, vol.33, issue.9, pp.1775-1784, 2006.

S. R. Binder and C. M. Litwin, Anti-phospholipid Antibodies and Smoking: An Overview, Clin Rev Allergy Immunol. août, vol.53, issue.1, pp.1-13, 2017.

P. K. Yadalam, K. Rajapandian, P. L. Ravishankar, K. Vartharajan, S. Subramaniam et al., Evaluation of anticardiolipin antibodies in tobacco users and non-tobacco users with severe chronic periodontal disease, J Int Soc Prev Community Dent. juin, vol.6, issue.3, pp.256-60, 2016.

V. Pengo, A. Ruffatti, C. Legnani, P. Gresele, D. Barcellona et al., Clinical course of high-risk patients diagnosed with antiphospholipid syndrome, J Thromb Haemost JTH. févr, vol.8, issue.2, pp.237-279, 2010.

A. Ruffatti, M. Tonello, A. Cavazzana, P. Bagatella, and V. Pengo, Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy, Thromb Res, vol.123, issue.3, pp.482-489, 2009.

V. Pengo, A. Ruffatti, C. Legnani, S. Testa, T. Fierro et al., Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study, Blood, vol.118, issue.17, pp.4714-4722, 2011.

, Le syndrome des antiphospholipides est une entité clinico-biologique dont la présentation clinique est polymorphe. Différentes formes ont été décrites de la forme thrombotique veineuse à la forme obstétricale en passant par le syndrome catastrophique des antiphospholipides, Chacune de ces formes ont leurs diagnostics différentiels pour lequel les traitements différents de celui du SAPL

M. Matériel,

, Les patients du CHU de Rouen ayant bénéficié d'une première sérologie aPL positive entre le 1 er janvier 2017 au 31 décembre 2019 et avec une sérologie de contrôle à 12 semaines ont été inclus. Les patients ont été répartis selon le profil évolutif de l'aPL en sérologie transitoire (cas), Notre étude est une étude rétrospective, observationnelle de type cas-témoins

, 01), la double positivité (OR : 0.14 ; p=0.05) et la présence d'Ac anticardiolipine en IgM (OR : 0.29 ; p=0.05) et d'Ac antiB2Gp1 en IgM (OR : 0 ; p=0.02) était prédictif d'un APL persistant. Aucun facteur clinique ou biologique n'était prédictif d'un aPL persistant en cas de thrombose artérielle ou veineuse initiale. Discussion L'absence de corrélation entre aPL persistant et maladies auto-immunes est probablement dû au fait que les ambulatoires avaient un test de confirmation en laboratoire de ville, Résultats : 71 patients ont été inclus. La simple positivité était prédictive d'une aPL transitoire, vol.36, p.10

, Mots clés : Syndrome des antiphospholipides